๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

IGF1 is a modifier of disease risk in hereditary non-polyposis colorectal cancer

โœ Scribed by Stuart G. Reeves; Dominique Rich; Cliff J. Meldrum; Kim Colyvas; Grzegorz Kurzawski; Janina Suchy; Jan Lubinski; Rodney J. Scott


Publisher
John Wiley and Sons
Year
2008
Tongue
French
Weight
109 KB
Volume
123
Category
Article
ISSN
0020-7136

No coin nor oath required. For personal study only.

โœฆ Synopsis


Abstract

Patients diagnosed with HNPCC harbouring a confirmed germline mutation in DNA mismatch repair (MMR) genes have an 80% lifetime risk of developing an epithelial malignancy. There is, however, considerable variation in the age of disease onset in these patients. Insulinโ€like growth factorโ€I (IGFI) has been implicated in colorectal cancer (CRC), and elevated plasma IGFI levels are associated with both sporadic and hereditary CRC risk. In this study, we further investigate the cytosineโ€adenine (CA) dinucleotide repeat polymorphism located near the promoter region of IGF1 and its relation to early onset CRC risk in 443 Australian and Polish MMR gene mutation carriers using DNA sequencing, Kaplanโ€Meier survival curves and Cox proportional hazard regression analysis. A significantly smaller number of IGF1 CA repeats was observed in the Polish patient population, which was associated with an earlier age of disease onset compared to the Australian patients. The threshold for the observed modifying effect was again shown to be in patients with 17 or less CA repeats compared to those with 18 or more. Furthermore, when MMR mutation group (i.e., MLH1 or MSH2), gender and family clustering were included in the final Cox model we observed a more robust trend for the role of the IGF1 CA repeat in predicting age of disease onset in HNPCC patients. In addition, this effect was shown to be equal in both MLH1 and MSH2 mutation carrier groups and not restricted to a particular MMR subgroup (p = 0.001). We conclude that the IGF1 CA repeat is an important modifier of disease onset in HNPCC and the first polymorphism to yield consistent results across different populations. ยฉ 2008 Wileyโ€Liss, Inc.


๐Ÿ“œ SIMILAR VOLUMES


The risk of brain tumours in hereditary
โœ H. F. A. Vasen; E. A. C. M. Sanders; B. G. Taal; F. M. Nagengast; G. Griffioen; ๐Ÿ“‚ Article ๐Ÿ“… 1996 ๐Ÿ› John Wiley and Sons ๐ŸŒ French โš– 417 KB ๐Ÿ‘ 2 views

Hereditary non-polyposis colorectal cancer (HNPCC) is known to be associated with several extracolonic cancers, e.g., cancers of the endometrium, stomach, urinary tract, small bowel and ovary. An association between HNPCC and brain tumours has also been reported, although previous risk analysis did

Life-time risk of different cancers in h
โœ Markku Aarnio; Jukka-Pekka Mecklin; Lauri A. Aaltonen; Minna Nystrรถm-Lahti; Heik ๐Ÿ“‚ Article ๐Ÿ“… 1995 ๐Ÿ› John Wiley and Sons ๐ŸŒ French โš– 431 KB ๐Ÿ‘ 1 views

Identification of hereditary non-polyporis colorectal cancer (HNPCC) indicates theoretical life-time risks of 50% for the descendants of an affected family member and of 100% for the true gene carriers. However, besides colorectal cancer (CRC), many other cancer types and sites are also involved, wh

Disease expression in Swiss hereditary n
โœ Karl Heinimann; Hansjakob Mรผller; Walter Weber; Rodney J. Scott ๐Ÿ“‚ Article ๐Ÿ“… 1997 ๐Ÿ› John Wiley and Sons ๐ŸŒ French โš– 100 KB ๐Ÿ‘ 2 views

The genetics of Hereditary Non-Polyposis Colorectal Cancer (HNPCC) has recently been established and found to be associated with DNA mismatch repair deficiency. As the molecular basis of this syndrome does not appear to predict any particular disease, we compared families selected according to the '

Features of gastric cancer in hereditary
โœ Markku Aarnio; Reijo Salovaara; Lauri A. Aaltonen; Jukka-Pekka Mecklin; Heikki J ๐Ÿ“‚ Article ๐Ÿ“… 1997 ๐Ÿ› John Wiley and Sons ๐ŸŒ French โš– 77 KB ๐Ÿ‘ 2 views

To identify characteristics of gastric cancer associated with hereditary non-polyposis colorectal cancer (HNPCC), we gathered clinical data and tumor samples relating to patients recorded in the Finnish HNPCC registry. Our series included 51 families with a characterized mutation and/or that met the